0 9 Induction Induction NNP 10 12 of of IN 13 17 IL-8 il-8 NN 18 28 expression expression NN 29 31 in in IN 32 33 T t NN 34 39 cells cell NNS 40 44 uses use VBZ 45 48 the the DT 49 53 CD28 cd28 NN 54 67 costimulatory costimulatory JJ 68 75 pathway pathway NN 75 76 . . . 78 82 IL-8 IL-8 NNP 82 83 , , , 84 85 a a DT 86 92 potent potent JJ 93 104 chemotactic chemotactic JJ 105 111 factor factor NN 112 115 for for IN 116 126 neutrophil neutrophil NN 127 139 granulocytes granulocyte NNS 140 143 and and CC 144 155 lymphocytes lymphocyte NNS 155 156 , , , 157 159 is be VBZ 160 161 a a DT 162 177 proinflammatory proinflammatory JJ 178 186 cytokine cytokine NN 187 195 secreted secrete VBN 196 198 by by IN 199 200 a a DT 201 208 variety variety NN 209 211 of of IN 212 216 cell cell NN 217 222 types type NNS 222 223 , , , 224 233 including include VBG 234 235 T t NN 236 241 cells cell NNS 241 242 . . . 243 254 Stimulation stimulation NN 255 257 of of IN 258 261 the the DT 262 266 CD28 cd28 NN 267 271 cell cell NN 272 279 surface surface NN 280 288 molecule molecule NN 289 297 delivers deliver VBZ 298 311 costimulatory costimulatory JJ 312 319 signals signal NNS 320 329 essential essential JJ 330 333 for for IN 334 344 lymphokine lymphokine NN 345 355 production production NN 356 358 in in IN 359 368 activated activate VBN 369 370 T t NN 371 376 cells cell NNS 377 380 via via IN 381 382 a a DT 383 392 conserved conserve VBN 393 401 sequence sequence NN 402 409 element element NN 410 415 found find VBN 416 418 in in IN 419 422 the the DT 423 431 promoter promoter NN 432 434 of of IN 435 442 several several JJ 443 453 lymphokine lymphokine NN 454 459 genes gene NNS 459 460 . . . 461 481 Anti-CD28-stimulated anti-cd28-stimulated JJ 482 483 T t NN 484 489 cells cell NNS 490 498 produced produce VBD 499 510 significant significant JJ 511 518 amounts amount NNS 519 521 of of IN 522 526 IL-8 il-8 NN 526 527 ; ; : 528 540 additionally additionally RB 540 541 , , , 542 555 costimulation costimulation NN 556 560 with with IN 561 569 anti-CD3 anti-cd3 JJ 570 573 and and CC 574 583 anti-CD28 anti-cd28 JJ 584 587 Abs ab NNS 588 596 resulted result VBD 597 599 in in IN 600 601 a a DT 602 613 synergistic synergistic JJ 614 623 induction induction NN 624 626 of of IN 627 631 IL-8 il-8 NN 632 641 secretion secretion NN 641 642 . . . 643 651 Sequence sequence NN 652 660 homology homology NN 660 661 , , , 662 668 single single JJ 669 679 nucleotide nucleotide NN 680 689 mutations mutation NNS 689 690 , , , 691 694 and and CC 695 704 anti-CD28 anti-cd28 JJ 705 707 Ab Ab NNP 708 719 stimulation stimulation NN 720 727 studies study NNS 728 739 established establish VBD 740 744 that that IN 745 748 the the DT 749 757 NF-kappa NF-kappa NNP 758 764 B-like b-like JJ 765 773 sequence sequence NN 774 776 in in IN 777 780 the the DT 781 789 promoter promoter NN 790 792 of of IN 793 796 the the DT 797 801 IL-8 il-8 NN 802 806 gene gene NN 807 817 functioned function VBD 818 820 as as IN 821 822 a a DT 823 827 CD28 cd28 NN 828 836 response response NN 837 844 element element NN 844 845 . . . 846 857 Furthermore furthermore RB 857 858 , , , 859 870 cyclosporin cyclosporin NN 871 872 A a NN 872 873 , , , 874 877 but but CC 878 881 not not RB 882 891 rapamycin rapamycin NN 891 892 , , , 893 900 blocked block VBD 901 904 the the DT 905 916 synergistic synergistic JJ 917 926 induction induction NN 927 929 of of IN 930 934 IL-8 il-8 NN 935 945 expression expression NN 946 954 achieved achieve VBN 955 959 with with IN 960 968 anti-CD3 anti-cd3 JJ 969 972 and and CC 973 982 anti-CD28 anti-cd28 JJ 983 996 costimulation costimulation NN 996 997 . . . 998 1001 The the DT 1002 1013 involvement involvement NN 1014 1016 of of IN 1017 1018 a a DT 1019 1023 CD28 cd28 NN 1024 1032 response response NN 1033 1040 element element NN 1041 1043 in in IN 1044 1047 the the DT 1048 1057 induction induction NN 1058 1060 of of IN 1061 1065 IL-8 il-8 NN 1066 1076 expression expression NN 1077 1079 in in IN 1080 1089 activated activate VBN 1090 1091 T t NN 1092 1097 cells cell NNS 1098 1101 may may MD 1102 1109 provide provide VB 1110 1113 new new JJ 1114 1122 insights insight NNS 1123 1127 into into IN 1128 1131 the the DT 1132 1144 pathogenesis pathogenesis NN 1145 1148 and and CC 1149 1160 persistence persistence NN 1161 1163 of of IN 1164 1170 immune immune JJ 1171 1180 disorders disorder NNS 1181 1194 characterized characterize VBN 1195 1197 by by IN 1198 1207 increased increase VBN 1208 1214 levels level NNS 1215 1217 of of IN 1218 1222 IL-8 il-8 NN 1222 1223 , , , 1224 1228 such such JJ 1229 1231 as as IN 1232 1241 psoriasis psoriasis NN 1242 1245 and and CC 1246 1256 rheumatoid rheumatoid JJ 1257 1266 arthritis arthritis NN 1266 1267 . . .